Drug recall · March 14, 2018
Labetalol Hydrochloride Injection recall
Why: Defective Container: Cracked glass at the rim surface of glass vials, covered by the stopper and crimp seal.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Labetalol Hydrochloride Injection, USP, 100 mg/ 20 mL (5 mg/mL), 20 mL Multidose Vial, Rx only, labeled as a) Hospira, Inc., Lake Forest, IL 60045, NDC 0409-2267-20; and b) NOVAPLUS, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-2267-25.
- Lots / codes
Lots: a) 74370DD, Exp 1FEB2019; 75035DD, 75115DD, Exp 1MAR2019; b) 74230DD, Exp 1FEB2019
- Quantity
- a) 137,975 vials; b) 40,143 vials
- Company
- Hospira Inc. A Pfizer Company, Mcpherson, KS
- Distribution
- Nationwide in the USA and Puerto Rico.
- Initiated
- February 20, 2018 · Voluntary: Firm initiated
- Classified
- March 2, 2018
- Reported
- March 14, 2018
- Ended
- April 2, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Labetalol
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.